The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
For the treatment of Clostridium difficile-associated diarrhea (CDAD), metronidazole and vancomycin remain the most commonly used agents. The major advantage of metronidazole is its low cost, while the advantage of oral vancomycin is a more favorable pharmacokinetic profile. The epidemiology and clinical severity of CDAD have changed due to the emergence of a hypervirulent strain (BI/NAP1/027). In 2010, the Infectious Diseases Society of America/Society for Health Care Epidemiology of America expert panel defined severe CDAD and recommended oral vancomycin to treat these patients. Metronidazole remains the preferred agent for treatment of mild to moderate CDAD.
Cape Fear Valley Health System, Roseboro, NC, USA.
Serina B
SB
Tart
D060433:Administration, Ophthalmic; D000900:Anti-Bacterial Agents / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000302:isolation & purification*; D003015:Clostridium Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D003967:Diarrhea / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D016527:Drug Costs; D006801:Humans; D008795:Metronidazole / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D012720:Severity of Illness Index; D014640:Vancomycin / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D008795:Metronidazole; D014640:Vancomycin
clostridium difficile treatment; metronidazole; oral vancomycin